{"id":2997,"date":"2026-11-10T06:26:00","date_gmt":"2026-11-10T06:26:00","guid":{"rendered":"https:\/\/admarebio.com\/?p=2997"},"modified":"2026-11-10T18:42:03","modified_gmt":"2026-11-10T18:42:03","slug":"epitopea-announces-first-patient-dosed-in-ovact-phase-1-1b-clinical-trial-of-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer","status":"publish","type":"post","link":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-announces-first-patient-dosed-in-ovact-phase-1-1b-clinical-trial-of-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer\/","title":{"rendered":"Epitopea Announces First Patient Dosed in OVACT Phase 1\/1b Clinical Trial of CryptiVax\u2122-1001 in Advanced High-Grade Serous Ovarian Cancer"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>CAMBRIDGE, UK and MONTREAL, CANADA, 9 November 2026<\/strong> \u2013 Epitopea, a clinical-stage, biotech company developing off-the-shelf, durable RNA-based cancer vaccines, announced today that the first patient has been successfully dosed in OVACT, its first-in-human Phase 1\/1b clinical trial evaluating its lead program, CryptiVax\u2122-1001, targeting advanced high-grade serous ovarian cancer (HGSOC).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07665515\" target=\"_blank\" rel=\"noopener\">OVACT<\/a> is a Phase 1\/1b dose escalation trial designed to evaluate the safety, tolerability, immunogenicity, and early clinical activity of CryptiVax\u2122-1001 in HRP+\/BRCA-wildtype advanced HGSOC patients. Up to 30 women will be enrolled into the trial across up to 10 leading clinical centres in the UK.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">HGSOC remains one of the most difficult-to-treat solid tumors, with around 80% of patients presenting with advanced or metastatic disease. While most women respond to first-line platinum chemotherapy, nearly all ultimately relapse and progress to platinum-resistant disease. Existing maintenance options are only effective in half of the ovarian cancer population and leave a major therapeutic gap among HRP+\/BRCA-wildtype patients.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Dr. Klaus Edvardsen, MD, PhD, Chief Medical Officer of Epitopea, commented, \u201cHGSOC is the most common and aggressive subtype of ovarian cancer. Treating the first patient with CryptiVax\u2122-1001 in our OVACT Phase 1\/1b trial for HGSOC is a major milestone for Epitopea. Epitopea\u2019s approach targets a novel repertoire of tumor-specific antigens that have been selected to provide broader patient benefit. We are motivated by the potential to provide meaningful durable treatment options for this underserved patient population.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Professor Susana Banerjee (MBBS MA PhD FRCP), the Chief Investigator of Epitopea\u2019s OVACT trial, Consultant Medical Oncologist and Research Lead for the Gynaecology Unit at The <a href=\"https:\/\/www.royalmarsden.nhs.uk\/\" target=\"_blank\" rel=\"noopener\">Royal Marsden<\/a> NHS Foundation Trust and Professor in Women\u2019s Cancers at The Institute of Cancer Research, London, said, \u201cIt is exciting to offer patients the option of the OVACT trial and I am delighted that we are underway with the first patient treated. The CryptiVax\u2122-1001 vaccine has the potential to meaningfully extend remission for women where currently available maintenance therapies deliver limited durable benefit.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>ENDS<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>About Epitopea<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Epitopea is a clinical-stage cancer immunotherapy company developing accessible, off-the-shelf RNA-based immunotherapies for hard-to-treat solid tumors.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Epitopea\u2019s pipeline is enabled by CryptoMap<sup>TM<\/sup>, a proprietary discovery engine that empirically identifies tumor-presented antigens arising from the dark genome, a previously inaccessible source of novel, tumor-specific targets. These antigens, known as Cryptigens<sup>TM<\/sup>, demonstrate high inter-patient sharing, enabling development of true off-the-shelf mRNA immunotherapies.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The company\u2019s lead candidate, CryptiVax\u2122-1001, is in the multi-centre Phase 1\/1b OVACT clinical trial for high-grade serous ovarian cancer. It is designed to drive targeted immune responses using a set of tumor-specific antigens chosen for their immunogenicity and broad patient coverage. Many patients with advanced cancers, including those with high-grade serous ovarian cancer, have limited treatment options offering durable responses, with few effective therapies available beyond those in biomarker-selected populations. Epitopea aims to address this considerable unmet need with broadly applicable, tumor-selective mRNA immunotherapies.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Backed by leading life-science investors, Epitopea operates from Cambridge, UK, and Montreal, Canada. For more information, visit\u202f<a href=\"https:\/\/www.epitopea.com\/\">www.epitopea.com<\/a>\u202fand follow the company on\u202f<a href=\"https:\/\/www.linkedin.com\/company\/epitopea\/\" target=\"_blank\" rel=\"noopener\">LinkedIn<\/a>.<\/p>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-794e3cfa wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/admarebio.com\/en\/building-companies\/portfolio\/\">Discover our portfolio companies<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, UK and MONTREAL, CANADA, 9 November 2026 \u2013 Epitopea, a clinical-stage, biotech company developing off-the-shelf, durable RNA-based cancer vaccines, announced today that the first patient has been successfully dosed [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":3010,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[29],"tags":[],"company":[78],"class_list":["post-2997","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-portfolio-companies"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Epitopea Announces First Patient Dosed in OVACT Phase 1\/1b Clinical Trial of CryptiVax\u2122-1001 in Advanced High-Grade Serous Ovarian Cancer | adMare<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/admarebio.com\/en\/news-events\/news-insights\/epitopea-announces-first-patient-dosed-in-ovact-phase-1-1b-clinical-trial-of-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Epitopea Announces First Patient Dosed in OVACT Phase 1\/1b Clinical Trial of CryptiVax\u2122-1001 in Advanced High-Grade Serous Ovarian Cancer | adMare\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, UK and MONTREAL, CANADA, 9 November 2026 \u2013 Epitopea, a clinical-stage, biotech company developing off-the-shelf, durable RNA-based cancer vaccines, announced today that the first patient has been successfully dosed [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-announces-first-patient-dosed-in-ovact-phase-1-1b-clinical-trial-of-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"adMare\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-10T06:26:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-10T18:42:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/11\/partnership-6-4.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Alexis Bouffioux\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alexis Bouffioux\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-announces-first-patient-dosed-in-ovact-phase-1-1b-clinical-trial-of-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-announces-first-patient-dosed-in-ovact-phase-1-1b-clinical-trial-of-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer\\\/\"},\"author\":{\"name\":\"Alexis Bouffioux\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/person\\\/87e6ba6ef08826d003854731e1971add\"},\"headline\":\"Epitopea Announces First Patient Dosed in OVACT Phase 1\\\/1b Clinical Trial of CryptiVax\u2122-1001 in Advanced High-Grade Serous Ovarian Cancer\",\"datePublished\":\"2026-11-10T06:26:00+00:00\",\"dateModified\":\"2026-11-10T18:42:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-announces-first-patient-dosed-in-ovact-phase-1-1b-clinical-trial-of-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer\\\/\"},\"wordCount\":525,\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-announces-first-patient-dosed-in-ovact-phase-1-1b-clinical-trial-of-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/partnership-6-4.png\",\"articleSection\":[\"Portfolio Companies\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-announces-first-patient-dosed-in-ovact-phase-1-1b-clinical-trial-of-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-announces-first-patient-dosed-in-ovact-phase-1-1b-clinical-trial-of-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer\\\/\",\"name\":\"Epitopea Announces First Patient Dosed in OVACT Phase 1\\\/1b Clinical Trial of CryptiVax\u2122-1001 in Advanced High-Grade Serous Ovarian Cancer | adMare\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-announces-first-patient-dosed-in-ovact-phase-1-1b-clinical-trial-of-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-announces-first-patient-dosed-in-ovact-phase-1-1b-clinical-trial-of-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/partnership-6-4.png\",\"datePublished\":\"2026-11-10T06:26:00+00:00\",\"dateModified\":\"2026-11-10T18:42:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-announces-first-patient-dosed-in-ovact-phase-1-1b-clinical-trial-of-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-announces-first-patient-dosed-in-ovact-phase-1-1b-clinical-trial-of-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-announces-first-patient-dosed-in-ovact-phase-1-1b-clinical-trial-of-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/partnership-6-4.png\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/partnership-6-4.png\",\"width\":1200,\"height\":628},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-announces-first-patient-dosed-in-ovact-phase-1-1b-clinical-trial-of-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News &#038; Events\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/news-events\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"News &#038; Insights\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/news-events\\\/news-insights\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Epitopea Announces First Patient Dosed in OVACT Phase 1\\\/1b Clinical Trial of CryptiVax\u2122-1001 in Advanced High-Grade Serous Ovarian Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\",\"name\":\"adMare\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/admarebio.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\",\"name\":\"adMare\",\"url\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"width\":915,\"height\":337,\"caption\":\"adMare\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/person\\\/87e6ba6ef08826d003854731e1971add\",\"name\":\"Alexis Bouffioux\",\"url\":\"#\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Epitopea Announces First Patient Dosed in OVACT Phase 1\/1b Clinical Trial of CryptiVax\u2122-1001 in Advanced High-Grade Serous Ovarian Cancer | adMare","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/admarebio.com\/en\/news-events\/news-insights\/epitopea-announces-first-patient-dosed-in-ovact-phase-1-1b-clinical-trial-of-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Epitopea Announces First Patient Dosed in OVACT Phase 1\/1b Clinical Trial of CryptiVax\u2122-1001 in Advanced High-Grade Serous Ovarian Cancer | adMare","og_description":"CAMBRIDGE, UK and MONTREAL, CANADA, 9 November 2026 \u2013 Epitopea, a clinical-stage, biotech company developing off-the-shelf, durable RNA-based cancer vaccines, announced today that the first patient has been successfully dosed [&hellip;]","og_url":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-announces-first-patient-dosed-in-ovact-phase-1-1b-clinical-trial-of-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer\/","og_site_name":"adMare","article_published_time":"2026-11-10T06:26:00+00:00","article_modified_time":"2026-11-10T18:42:03+00:00","og_image":[{"width":1200,"height":628,"url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/11\/partnership-6-4.png","type":"image\/png"}],"author":"Alexis Bouffioux","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Alexis Bouffioux","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-announces-first-patient-dosed-in-ovact-phase-1-1b-clinical-trial-of-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer\/#article","isPartOf":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-announces-first-patient-dosed-in-ovact-phase-1-1b-clinical-trial-of-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer\/"},"author":{"name":"Alexis Bouffioux","@id":"https:\/\/admarebio.com\/en\/#\/schema\/person\/87e6ba6ef08826d003854731e1971add"},"headline":"Epitopea Announces First Patient Dosed in OVACT Phase 1\/1b Clinical Trial of CryptiVax\u2122-1001 in Advanced High-Grade Serous Ovarian Cancer","datePublished":"2026-11-10T06:26:00+00:00","dateModified":"2026-11-10T18:42:03+00:00","mainEntityOfPage":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-announces-first-patient-dosed-in-ovact-phase-1-1b-clinical-trial-of-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer\/"},"wordCount":525,"publisher":{"@id":"https:\/\/admarebio.com\/en\/#organization"},"image":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-announces-first-patient-dosed-in-ovact-phase-1-1b-clinical-trial-of-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/11\/partnership-6-4.png","articleSection":["Portfolio Companies"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-announces-first-patient-dosed-in-ovact-phase-1-1b-clinical-trial-of-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer\/","url":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-announces-first-patient-dosed-in-ovact-phase-1-1b-clinical-trial-of-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer\/","name":"Epitopea Announces First Patient Dosed in OVACT Phase 1\/1b Clinical Trial of CryptiVax\u2122-1001 in Advanced High-Grade Serous Ovarian Cancer | adMare","isPartOf":{"@id":"https:\/\/admarebio.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-announces-first-patient-dosed-in-ovact-phase-1-1b-clinical-trial-of-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer\/#primaryimage"},"image":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-announces-first-patient-dosed-in-ovact-phase-1-1b-clinical-trial-of-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/11\/partnership-6-4.png","datePublished":"2026-11-10T06:26:00+00:00","dateModified":"2026-11-10T18:42:03+00:00","breadcrumb":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-announces-first-patient-dosed-in-ovact-phase-1-1b-clinical-trial-of-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-announces-first-patient-dosed-in-ovact-phase-1-1b-clinical-trial-of-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-announces-first-patient-dosed-in-ovact-phase-1-1b-clinical-trial-of-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer\/#primaryimage","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/11\/partnership-6-4.png","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/11\/partnership-6-4.png","width":1200,"height":628},{"@type":"BreadcrumbList","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-announces-first-patient-dosed-in-ovact-phase-1-1b-clinical-trial-of-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/admarebio.com\/en\/"},{"@type":"ListItem","position":2,"name":"News &#038; Events","item":"https:\/\/admarebio.com\/en\/news-events\/"},{"@type":"ListItem","position":3,"name":"News &#038; Insights","item":"https:\/\/admarebio.com\/en\/news-events\/news-insights\/"},{"@type":"ListItem","position":4,"name":"Epitopea Announces First Patient Dosed in OVACT Phase 1\/1b Clinical Trial of CryptiVax\u2122-1001 in Advanced High-Grade Serous Ovarian Cancer"}]},{"@type":"WebSite","@id":"https:\/\/admarebio.com\/en\/#website","url":"https:\/\/admarebio.com\/en\/","name":"adMare","description":"","publisher":{"@id":"https:\/\/admarebio.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/admarebio.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/admarebio.com\/en\/#organization","name":"adMare","url":"https:\/\/admarebio.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/admarebio.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","width":915,"height":337,"caption":"adMare"},"image":{"@id":"https:\/\/admarebio.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/admarebio.com\/en\/#\/schema\/person\/87e6ba6ef08826d003854731e1971add","name":"Alexis Bouffioux","url":"#"}]}},"_links":{"self":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/2997","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/comments?post=2997"}],"version-history":[{"count":2,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/2997\/revisions"}],"predecessor-version":[{"id":2999,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/2997\/revisions\/2999"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/media\/3010"}],"wp:attachment":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/media?parent=2997"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/categories?post=2997"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/tags?post=2997"},{"taxonomy":"company","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/company?post=2997"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}